Insider transaction details
Tango Therapeutics NASDAQ:TNGX reported that Chief Financial Officer Daniella Beckman sold a total of 10,317 shares of common stock on February 3, 2026, for aggregate proceeds of approximately $126,530. The trades occurred across two transactions with execution prices reported in a range from $12.2573 to $12.8971 per share. At the time of reporting the company’s shares were trading at $12.32, and the firm’s market capitalization was listed at $1.66 billion, following a one-year return of 267.76 percent.
Form 4 specifics and rationale
The Form 4 filing submitted to the Securities and Exchange Commission breaks the activity down further. Beckman disposed of 10,204 shares at a weighted average price of $12.2573, with individual sale prices within a band of $11.88 to $12.875. A separate sale of 113 shares was reported at a weighted average price of $12.8971, with sale prices recorded between $12.88 and $12.91. The filing’s footnotes state these sales were made to satisfy tax withholding obligations arising from the vesting of restricted stock units.
Compensation awards to the CFO
On February 2, 2026, Beckman was credited with 44,330 restricted stock units (RSUs) issued at no cost to her, which will vest over a three-year schedule. In addition to the RSUs, Beckman received options to purchase 265,980 shares of common stock with an exercise price of $11.94; those options vest over a four-year period. After recording the sales and the awards, Beckman is reported to directly own 184,297 shares of Tango Therapeutics common stock.
Market performance and analyst view
Third-party data cited in the company disclosure highlights that Tango’s shares have returned 78.29 percent over the past six months and 267.76 percent over the last year. Analysts retain a Strong Buy consensus on the stock, although the same dataset identifies Tango as appearing overvalued at current market levels. Additional balance sheet and market metrics disclosed include a current ratio of 8.88, a Price/Book ratio of 10.37, and a beta of 1.76, indicating the company carries higher volatility relative to the broader market.
Capital raising and analyst coverage
The company has entered into an agreement with Leerink Partners LLC to establish an at-the-market offering program for up to $100 million of common stock, under which Tango may sell shares at its discretion with Leerink acting as sales agent. Separately, Stifel has maintained a Buy rating on the shares and set a price target of $15.00, citing updates to the company’s pipeline and strategic priorities. Stifel’s research specifically noted the potential of vopimetostat as a potential best-in-class PRMT5 inhibitor.
Leadership and governance developments
Tango Therapeutics announced an executive transition in which Malte Peters will assume the role of Chief Executive Officer, succeeding Barbara Weber. Weber is slated to transition to the position of Executive Chair in 2026. The company also added Sung Lee to its Board of Directors, with the filing noting Lee brings more than two decades of finance leadership experience. These personnel changes accompany the other governance and capital actions disclosed by the company.
Context and investor considerations
The combination of sizeable equity awards to the CFO, the tax-withholding-related disposition of a portion of those awards, an active at-the-market program, ongoing analyst enthusiasm, and a leadership change represent a cluster of developments that bear monitoring for shareholders. The company’s liquidity metric is robust by the reported current ratio, while valuation measures and elevated beta signal attributes investors frequently weigh when assessing exposure to biotechnology and specialty therapeutics firms.
Key points
- Insider sale: CFO Daniella Beckman sold 10,317 shares on February 3, 2026, totaling about $126,530 to cover tax withholding tied to RSU vesting.
- Compensation grants: Beckman received 44,330 RSUs vesting over three years and options for 265,980 shares at an $11.94 exercise price vesting over four years; she now directly holds 184,297 shares.
- Corporate actions: Tango launched a $100 million at-the-market offering with Leerink Partners and announced a CEO transition and a new board appointment; Stifel maintains a $15.00 price target and Buy rating.
Risks and uncertainties
- Valuation risk - InvestingPro data indicates the company may be overvalued at current prices, which may influence investor returns and market sentiment.
- Dilution risk - The at-the-market offering allows the company to sell additional shares, which could dilute existing shareholders if executed.
- Volatility risk - The company’s beta of 1.76 points to greater price volatility compared with the broader market, a relevant consideration for investors in the biotech sector.
The facts presented here derive from the company’s regulatory filing and publicly disclosed corporate actions. Investors should consult primary filings and company disclosures for further detail.